Sanofi India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 47.1%)
- ✓Efficient capital deployment (ROCE 49.2%)
- ✓Attractively valued vs sector (P/E 17.8x vs industry 54.4x)
- ✓Virtually debt-free
- ✓Regular dividends — yield 2.2%
- ✓Near 52-week low — potential value zone (₹3,054)
Concerns
- ✗High premium to book value (P/B 9.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SANOFI · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| FII | 6.31% | 6.11% | 5.81% | 5.78% | 5.64% | 5.58% |
| DII | 22.51% | 22.88% | 22.60% | 22.62% | 22.94% | 23.02% |
| Public | 10.78% | 10.61% | 11.21% | 11.20% | 11.04% | 11.01% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 48 Per Share
Interim Dividend - Rs 75 Per Share
Dividend - Rs 117 Per Share
Demerger
Annual General Meeting
Dividend - Rs 117 Per Share
Interim Dividend - Rs 50 Per Share
Latest News
All news →Sanofi India shares unaffected by routine regulatory filing
*Sanofi India shares unaffected by routine regulatory filing.* The company submitted a general update to the NSE under SEBI listing regulations. No financial or operational impact is expected from this disclosure. It is a standard compliance requirement with no material changes reported. 📊 *STOCKS:* SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
12 stocks set ex-dates for dividends, splits, bonuses next week
*12 stocks including Sanofi India, Schaeffler, and CRISIL announce ex-dates next week for dividend payouts up to **₹101**, bonus issues, and stock splits.* Corporate actions include distributions and capital restructuring. Traders should note ex-date implications for positions and settlement. Portfolio adjustments advised for affected holdings. 📊 *STOCKS:* SANOFI | SCHAEFFLER | CRISIL | 🏢 *SECTOR:* Multi-sector | #MEDIUMIMPACT #dividend
Sanofi India posts strong earnings with positive momentum ahead
*Sanofi India demonstrates strong earnings performance with positive catalysts beyond current results.* The pharmaceutical company is showing **promising earnings** trajectory with **additional growth drivers** on the horizon. Analysts indicate further upside potential beyond reported numbers, suggesting momentum continuation. This positions the stock favorably for medium-term investors tracking pharma sector strength. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #EarningsBeat
Sanofi India forward P/E ratio updated on TradingView
*Sanofi India forward P/E ratio updated on TradingView.* The data reflects revised earnings expectations, though no fundamental change in operations was reported. **Forward P/E** stands at **34.2x** as per latest metrics. This update is informational for traders assessing valuation multiples. 📊 *STOCKS:* SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #P/Eratio
Sanofi India partners MP Health Mission for rare disease care
*Sanofi India partners MP Health Mission for rare disease care.* The collaboration with NHM Madhya Pradesh aims to expand access to treatment for non-communicable and rare diseases. Focus will be on improving diagnosis and patient support systems. **No financial details** of the partnership were disclosed. 📊 *STOCKS:* SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #pharma
Sanofi India partners with MP govt for NCD, rare disease care
*Sanofi India partners with MP govt for NCD, rare disease care.* The collaboration with NHM Madhya Pradesh aims to enhance healthcare access for non-communicable and rare diseases. While the move supports long-term patient outreach, it does not involve a significant financial outlay. No immediate revenue impact is expected. 📊 *STOCKS:* SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Financials
Quarterly Results
| Metric | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹515 Cr ▼1.7% | ₹524 Cr ▲12.9% | ₹464 Cr ▼9.2% | ₹511 Cr ▲9.0% | ₹469 Cr ▼4.5% | ₹491 Cr ▼4.7% | ₹515 Cr |
| Op. Profit | ₹118 Cr ▼1.7% | ₹120 Cr ▲3.4% | ₹116 Cr ▼15.3% | ₹137 Cr ▲37.0% | ₹100 Cr ▼12.3% | ₹114 Cr ▼6.6% | ₹122 Cr |
| OPM | 23.0% ▲0.0% | 23.0% ▼8.0% | 25.0% ▼7.4% | 27.0% ▲28.6% | 21.0% ▼8.7% | 23.0% ▼4.2% | 24.0% |
| Net Profit | ₹91 Cr ▲11.0% | ₹82 Cr ▼20.4% | ₹103 Cr ▼24.8% | ₹137 Cr ▼0.7% | ₹138 Cr ▼9.2% | ₹152 Cr ▲23.6% | ₹123 Cr |
| EPS (₹) | 39.7 ▲11.1% | 35.74 ▼20.3% | 44.87 ▼24.4% | 59.39 ▼0.8% | 59.87 ▼9.3% | 66.04 ▲23.6% | 53.43 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Dec 2024 | Dec 2023 |
|---|---|---|
| Revenue | ₹2.0K Cr ▲0.9% | ₹2.0K Cr |
| Expenses | ₹1.5K Cr ▲0.9% | ₹1.5K Cr |
| Op. Profit | ₹491 Cr ▲0.6% | ₹488 Cr |
| OPM | 24.0% ▲0.0% | 24.0% |
| Other Income | ₹78 Cr ▼75.4% | ₹317 Cr |
| Interest | ₹2 Cr ▲0.0% | ₹2 Cr |
| Depreciation | ₹37 Cr ▲2.8% | ₹36 Cr |
| PBT | ₹531 Cr ▼30.8% | ₹767 Cr |
| Tax % | 22.0% ▲4.8% | 21.0% |
| Net Profit | ₹413 Cr ▼31.5% | ₹603 Cr |
| EPS (₹) | 179.7 ▼31.4% | 262.13 |
| Div Payout | 65.0% ▲1.6% | 64.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Dec 2024 | Dec 2023 |
|---|---|---|
| Liabilities | ||
| Equity Capital | ₹23 Cr ▲0.0% | ₹23 Cr |
| Reserves | ₹838 Cr ▼15.5% | ₹992 Cr |
| Borrowings | ₹19 Cr ▲0.0% | ₹19 Cr |
| Other Liabilities | ₹732 Cr ▲7.5% | ₹681 Cr |
| Total Liabilities | ₹1.6K Cr ▼6.0% | ₹1.7K Cr |
| Assets | ||
| Fixed Assets | ₹312 Cr ▼1.0% | ₹315 Cr |
| CWIP | ₹18 Cr ▲12.5% | ₹16 Cr |
| Investments | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹1.3K Cr ▼7.4% | ₹1.4K Cr |
| Total Assets | ₹1.6K Cr ▼6.0% | ₹1.7K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Dec 2024 | Dec 2023 |
|---|---|---|
| Operating CF | ₹462 Cr ▲100.9% | ₹230 Cr |
| Investing CF | ₹-180 Cr ▼573.7% | ₹38 Cr |
| Financing CF | ₹-392 Cr ▲55.4% | ₹-878 Cr |
| Net Cash Flow | ₹-111 Cr ▲81.8% | ₹-610 Cr |
| Free Cash Flow | ₹426 Cr ▲93.6% | ₹220 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Dec 2024 | Dec 2023 |
|---|---|---|
| Debtor Days | 42d ▲75.0% | 24d |
| Inventory Days | 186d ▼26.8% | 254d |
| Days Payable | 151d ▲34.8% | 112d |
| Cash Conv. Cycle | 77d ▼53.9% | 167d |
| Working Capital Days | 20d ▼42.9% | 35d |
| ROCE | 49.0% | — |
Source: Screener.in · Lower days = better efficiency